Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Using Biomarkers to Predict TB Treatment Duration
NCT02821832Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isoniazid, rifampicin, pyrazinamide, ethambutol in pulmonary tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2017; status: completed.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02821832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821832.